Contact lenses

In the year-ago quarter, results were also boosted by an after-tax gain of $368 million from the breakup fee J&J received after medical device maker Guidant Corp.

backed out of an acquisition agreement and instead was purchased by Boston Scientific Corp.

The story continues below...

This article Email this page My Canadian Business Join our advisory panel Analysts surveyed by Thomson Financial had expected earnings per share of $1.05 and sales of $14.44 billion.

Sales totaled $15.04 billion, up nearly 16 percent from $12.99 billion a year earlier.

Operational sales growth, which excludes the impact of new products and currency exchange rates, was 6.3 percent.

Revenues from the medical devices and diagnostics division edged up 6.2 percent to $5.32 billion, hurt by a 14 percent slide at Cordis, J&J's cardiovascular device business.

Sales of Cordis' drug-coated stents, tiny metal scaffolds that prop open arteries and slowly release medicine, were problematic, Chief Financial Officer Dominic C...

Read more...